EpCAM, a potential therapeutic target for esophageal squamous cell carcinoma

Annals of Surgical Oncology

Volumn 21, Issue SUPPL. 3, 2014, Pages

  Matsuda, Tatsuo ^a   Takeuchi, Hiroya ^a   Matsuda, Sachiko ^a   Hiraiwa, Kunihiko ^a   Miyasho, Taku ^b   Okamoto, Minoru ^b   Kawasako, Kazufumi ^b   Nakamura, Rieko ^a   Takahashi, Tsunehiro ^a   Wada, Norihito ^a   Kawakubo, Hirofumi ^a   Saikawa, Yoshiro ^a   Omori, Tai ^a   Kitagawa, Yuko ^a  

^a KEIO UNIVERSITY   (Japan)

^b RAKUNO GAKUEN UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CATUMAXOMAB; EPITHELIAL CELL ADHESION MOLECULE; SHORT HAIRPIN RNA; BISPECIFIC ANTIBODY; CELL ADHESION MOLECULE; EPCAM PROTEIN, HUMAN; MESSENGER RNA; SMALL INTERFERING RNA; TUMOR ANTIGEN; TUMOR MARKER;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL LINE; CANCER SURGERY; CANCER SURVIVAL; CARCINOGENESIS; CCND1 GENE; CCNE2 GENE; CELL PROLIFERATION; DOWN REGULATION; DRUG TARGETING; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; FEMALE; GENE; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MOUSE; NONHUMAN; PROTEIN EXPRESSION; ANIMAL; ANTAGONISTS AND INHIBITORS; APOPTOSIS; CANCER STAGING; CARCINOMA, SQUAMOUS CELL; DNA MICROARRAY; ENZYME IMMUNOASSAY; ESOPHAGEAL NEOPLASMS; FLOW CYTOMETRY; FOLLOW UP; GENE EXPRESSION PROFILING; GENETICS; LYMPH NODE METASTASIS; METABOLISM; MORTALITY; NUDE MOUSE; PROGNOSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL RATE; TUMOR CELL CULTURE; TUMOR INVASION; WESTERN BLOTTING; CONTROLLED STUDY; GENE EXPRESSION; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; PROTEIN TARGETING; TUMOR GROWTH;

ANIMALS; ANTIBODIES, BISPECIFIC; ANTIGENS, NEOPLASM; APOPTOSIS; BLOTTING, WESTERN; CARCINOMA, SQUAMOUS CELL; CELL ADHESION MOLECULES; CELL PROLIFERATION; ESOPHAGEAL NEOPLASMS; FEMALE; FLOW CYTOMETRY; FOLLOW-UP STUDIES; GENE EXPRESSION PROFILING; HUMANS; IMMUNOENZYME TECHNIQUES; LYMPHATIC METASTASIS; MALE; MICE; MICE, NUDE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; SURVIVAL RATE; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

EID: 84903279338     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-014-3579-8     Document Type: Article

References (32)

1. Pennathur A, Gibson MK, Jobe BA, Luketich JD. Oesophageal carcinoma. Lancet. 2013;381:400-12.
2. Brenner B, Ilson DH, Minsky BD. Treatment of localized esophageal cancer. Semin Oncol. 2004;31:554-65. (Pubitemid 39070273)
3. Enzinger PC, Mayer RJ. Esophageal cancer. N Engl J Med. 2003;349:2241-52. (Pubitemid 37485141)
4. Yamazaki M, Yamashita Y, Kubo N, Yashiro M, Ohira M, Ako E, et al. Concurrent Biological Targeting Therapy of Squamous Cell Carcinoma of the Esophagus with Cetuximab and Trastuzumab. Oncol Rep. 2012;28:49-54.
5. Lorenzen S, Schuster T, Porschen R, Al-Batran SE, Hofheinz R, Thuss-Patience P, et al. Cetuximab plus cisplatin-5-fluorouracil versus cisplatin-5-fluorouracil alone in first-line metastatic squamous cell carcinoma of the esophagus: a randomized phase II study of the Arbeitsgemeinschaft Internistische Onkologie. Ann Oncol. 2009;20:1667-73.
6. Herlyn M, Steplewski Z, Herlyn D, Koprowski H. Colorectal carcinoma-specific antigen: detection by means of monoclonal antibodies. Proc Natl Acad Sci U S A. 1979;76:1438-42. (Pubitemid 9136880)
7. Patriarca C, Macchi RM, Marschner AK, Mellstedt H. Epithelial cell adhesion molecule expression (CD326) in cancer: a short review. Cancer Treat Rev. 2012;38:68-75.
8. Imrich S, Hachmeister M, Gires O. EpCAM and its potential role in tumor-initiating cells. Cell Adh Migr. 2012;6:30-8.
9. Munz M, Baeuerle PA, Gires O. The emerging role of EpCAM in cancer and stem cell signaling. Cancer Res. 2009;69:5627-9.
10. Went P, Vasei M, Bubendorf L, Terracciano L, Tornillo L, Riede U, et al. Frequent high-level expression of the immunotherapeutic target Ep-CAM in colon, stomach, prostate and lung cancers. Br J Cancer. 2006;94:128-35. (Pubitemid 43088552)
11. Varga M, Obrist P, Schneeberger S, Muhlmann G, Felgel-Farnholz C, Fong D, et al. Overexpression of epithelial cell adhesion molecule antigen in gallbladder carcinoma is an independent marker for poor survival. Clin Cancer Res. 2004;10:3131-6. (Pubitemid 38619694)
12. Seligson DB, Pantuck AJ, Liu X, Huang Y, Horvath S, Bui MH, et al. Epithelial cell adhesion molecule (KSA) expression: pathobiology and its role as an independent predictor of survival in renal cell carcinoma. Clin Cancer Res. 2004;10:2659-69. (Pubitemid 38509139)
13. Spizzo G, Went P, Dirnhofer S, Obrist P, Simon R, Spichtin H, et al. High Ep-CAMexpression is associated with poor prognosis in nodepositive breast cancer. Breast Cancer Res Treat. 2004;86:207-13. (Pubitemid 39070963)
14. Yanamoto S, Kawasaki G, Yoshitomi I, Iwamoto T, Hirata K, Mizuno A. Clinicopathologic significance of EpCAM expression in squamous cell carcinoma of the tongue and its possibility as a potential target for tongue cancer gene therapy. Oral Oncol. 2007;43:869-77. (Pubitemid 47369249)
15. Heiss MM, Murawa P, Koralewski P, Kutarska E, Kolesnik OO, Ivanchenko VV, et al. The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: results of a prospective randomized phase II/III trial. Int J Cancer. 2010;127:2209-21.
16. Nagrath S, Sequist LV, Maheswaran S, Bell DW, Irimia D, Ulkus L, et al. Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature. 2007;450:1235-9.
17. Hiraiwa K, Takeuchi H, Hasegawa H, Saikawa Y, Suda K, Ando T, et al. Clinical significance of circulating tumor cells in blood from patients with gastrointestinal cancers. Ann Surg Oncol. 2008;15:3092-100.
18. Ruf P, Gires O, Jager M, Fellinger K, Atz J, Lindhofer H. Characterisation of the new EpCAM-specific antibody HO-3: implications for trifunctional antibody immunotherapy of cancer. Br J Cancer. 2007;97:315-21. (Pubitemid 47196752)
19. Momburg F, Moldenhauer G, Hammerling GJ, Moller P. Immunohistochemical study of the expression of a Mr 34,000 human epithelium-specific surface glycoprotein in normal and malignant tissues. Cancer Res. 1987;47:2883-91. (Pubitemid 17113431)
20. Schmidt M, Hasenclever D, Schaeffer M, Boehm D, Cotarelo C, Steiner E, et al. Prognostic effect of epithelial cell adhesion molecule overexpression in untreated node-negative breast cancer. Clin Cancer Res. 2008;14:5849-55.
21. Gastl G, Spizzo G, Obrist P, Dunser M, Mikuz G. Ep-CAM overexpression in breast cancer as a predictor of survival. Lancet. 2000;356:1981-2.
22. Spizzo G,WentP, Dirnhofer S, Obrist P,MochH, Baeuerle PA,et al. Overexpressionof epithelial celladhesionmolecule(Ep-CAM)isan independent prognostic marker for reduced survival of patients with epithelial ovarian cancer. Gynecol Oncol. 2006;103:483-8.
23. Osta WA, Chen Y, Mikhitarian K, Mitas M, Salem M, Hannun YA, et al. EpCAM is overexpressed in breast cancer and is a potential target for breast cancer gene therapy. Cancer Res. 2004;64:5818-24. (Pubitemid 39095582)
24. Litvinov SV, van Driel W, van Rhijn CM, Bakker HA, van Krieken H, Fleuren GJ, et al. Expression of Ep-CAM in cervical squamous epithelia correlates with an increased proliferation and the disappearance of markers for terminal differentiation. Am J Pathol. 1996;148:865-75. (Pubitemid 126660678)
25. Munz M, Kieu C, Mack B, Schmitt B, Zeidler R, Gires O. The carcinoma-associated antigen EpCAM upregulates C-myc and induces cell proliferation. Oncogene. 2004;23:5748-58. (Pubitemid 39093020)
26. Munz M, Zeidler R, Gires O. The tumour-associated antigen EpCAM upregulates the fatty acid binding protein E-FABP. Cancer Lett. 2005;225:151-7. (Pubitemid 40732778)
27. Fujii S, Tominaga O, Nagawa H, Tsuno N, Nita ME, Tsuruo T, et al. Quantitative analysis of the cyclin expression in human esophageal cancer cell lines. J Exp Clin Cancer. 1998;17:491-6. (Pubitemid 29083425)
28. Shinozaki H, Ozawa S, Ando N, Tsuruta H, Terada M, Ueda M, et al. Cyclin D1 amplification as a new predictive classification for squamous cell carcinoma of the esophagus, adding gene information. Clin Cancer Res. 1996;2:1155-61. (Pubitemid 26238446)
29. Takeuchi H, Ozawa S, Ando N, Shih CH, Koyanagi K, Ueda M, et al. Altered p16/MTS1/CDKN2 and cyclin D1/PRAD-1 gene expression is associated with the prognosis of squamous cell carcinoma of the esophagus. Clin Cancer Res. 1997;3:2229-36. (Pubitemid 28133140)
30. Dalerba P, Dylla SJ, Park IK, Liu R, Wang X, Cho RW, et al. Phenotypic characterization of human colorectal cancer stem cells. Proc Nat Acad Sci U S A. 2007;104:10158-63. (Pubitemid 47175279)
31. Yamashita T, Ji J, Budhu A, Forgues M, Yang W, Wang HY, et al. EpCAM-positive hepatocellular carcinoma cells are tumorinitiating cells with stem/progenitor cell features. Gastroenterology. 2009;136:1012-24.
32. Marhaba R, Klingbeil P, Nuebel T, Nazarenko I, Buechler MW, Zoeller M. CD44 and EpCAM: cancer-initiating cell markers. Curr Mol Med. 2008;8:784-804.